









Markets
/
Stocks
/
nasdaq-mrk
/

Merck & Co Inc

MRK



View Detailed Chart

100.300USD

+1.320+1.33%

Close 12/12, 16:00（ET）Quotes delayed by 15 min

249.48BMarket Cap

13.24P/E TTM



Merck & Co Inc

100.300

+1.320+1.33%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+1.33%

5 Days

+0.58%

1 Month

+7.94%

6 Months

+22.75%

Year to Date

+0.82%

1 Year

-1.67%

View Detailed Chart

TradingKey Stock Score of Merck & Co Inc

Currency: USD Updated: 2025-12-12

Key Insights

Merck & Co Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 10/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 104.78.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Merck & Co Inc's Score

Industry at a Glance

Industry Ranking

10 / 159

Overall Ranking

50 / 4592

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 30 analysts

Buy

Current Rating

104.781

Target Price

+5.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Merck & Co Inc Highlights

StrengthsRisks

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 64.17B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 46.40%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 46.40%.

Undervalued

The company’s latest PE is 13.24, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.02B shares, decreasing 2.22% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 46.76K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.02.

Merck & Co Inc News

Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact

TradingKey - U.S. pharmaceutical giant Merck (MRK.US) has announced a roughly $10 billion deal to acquire U.K.-based biopharma firm Verona Pharma (VRNA.US), marking a major move into the respiratory disease treatment space.

TradingKeyThu, Jul 10

200% Drug Tariff Ultimatum by Trump: Are Patients the Victims of Tariffs?

TradingKey - During a Cabinet meeting at the White House on July 8, Trump announced plans to impose tariffs of up to 200% on imported drugs, requiring pharmaceutical companies to relocate their production chains to the United States and granting them a 1 to 1.5-year adjustment period. If companies..

TradingKeyWed, Jul 9

Merck to Acquire Verona for $10 Billion — A Major Move into Respiratory Care, Shares of VRNA Surge 20%

TradingKey - According to a report by the Financial Times, U.S. pharmaceutical giant Merck (MRK.US) is nearing a deal to acquire Verona Pharma (VRNA.US) for $10 billion, marking Merck’s largest biopharma acquisition since 2023. The acquisition will expand Merck’s presence in the respiratory disease

TradingKeyWed, Jul 9

Trump executive order demands pharma industry price cuts

WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.

ReutersTue, May 13

Merck & Co Inc reports results for the quarter ended December 31 - Earnings Summary

Merck & Co Inc MRK.N reported quarterly adjusted earnings of $1.72 per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 3 cents. The mean expectation of sixteen analysts for the quarter was for earnings of $1.62 per share. Wall ...

ReutersTue, Feb 4

U.S. STOCKS ON THE MOVE-Merck & Co, Sirius XM Holdings, Palantir Technologies

Eikon search string for individual stock moves: The Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv/3dKUyB8U.S. stock index futures were slightly lower on Tuesday as investors stayed away from risky assets after China deployed retaliatory tariffs...

ReutersTue, Feb 4